InsiderTrades.com logo
JD Vance Predicts: Wall Street vs. Trump & Your Money
From Priority Gold   |   Ad
Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.
Get your free guide NOW before it's too late.

Brian Baker Biography and Net Worth

SVP of Turning Point Therapeutics
  • LinkedIn
  • Phone
  • Email
  • Website


Brian L. Baker CPA serves as Vice President - Finance and Administration of the Company. Previously, Mr. Baker served as the Vice President, Finance at Cleave Biosciences, Inc. from February 2013 until July 2017. From 2011 through 2013, Mr. Baker worked as an independent finance consultant to multiple companies in the life science industry. From 2006 through 2010, Mr. Baker held positions of increasing responsibility, including Vice President Finance and Principal Accounting Officer, with Phenomix Corporation. From 2000 through 2006, Mr. Baker held positions of increasing responsibility with Cengent Therapeutics, Inc., (previously Structural Bioinformatics, Inc.). Mr. Baker began his accounting career with Pricewaterhouse Coopers (previously Price Waterhouse) from 1996 through 2000. Mr. Baker received a B.S. in Business Administration—Accounting and an M.S. in Business Administration—Information Systems from San Diego State University. Mr. Baker maintains an active certified public accounting license in the state of California.

What is Brian Lee Baker's net worth?

The estimated net worth of Brian Lee Baker is at least $312,857.16 as of March 23rd, 2021. Mr. Baker owns 4,116 shares of Turning Point Therapeutics stock worth more than $312,857 as of November 25th. This net worth approximation does not reflect any other assets that Mr. Baker may own. Learn More about Brian Lee Baker's net worth.

How do I contact Brian Lee Baker?

The corporate mailing address for Mr. Baker and other Turning Point Therapeutics executives is 10628 SCIENCE CENTER DRIVE SUITE 225, SAN DIEGO CA, 92121. Turning Point Therapeutics can also be reached via phone at (858) 926-5251 and via email at [email protected]. Learn More on Brian Lee Baker's contact information.

Has Brian Lee Baker been buying or selling shares of Turning Point Therapeutics?

Brian Lee Baker has not been actively trading shares of Turning Point Therapeutics during the past quarter. Most recently, Brian Lee Baker sold 28,435 shares of the business's stock in a transaction on Tuesday, March 23rd. The shares were sold at an average price of $100.65, for a transaction totalling $2,861,982.75. Following the completion of the sale, the senior vice president now directly owns 4,116 shares of the company's stock, valued at $414,275.40. Learn More on Brian Lee Baker's trading history.

Who are Turning Point Therapeutics' active insiders?

Turning Point Therapeutics' insider roster includes Mark Alles (Director), Brian Baker (SVP), Athena Countouriotis (CEO), Jingrong Cui (Director), Mohammad Hirmand (EVP), Annette North (EVP), Andrew Partridge (EVP), Siegfried Reich (EVP), and Paolo Tombesi (CFO). Learn More on Turning Point Therapeutics' active insiders.

Brian Lee Baker Insider Trading History at Turning Point Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/23/2021Sell28,435$100.65$2,861,982.754,116View SEC Filing Icon  
1/7/2021Sell31,238$122.26$3,819,157.88View SEC Filing Icon  
4/22/2019Buy2,800$18.00$50,400.00View SEC Filing Icon  
See Full Table

Brian Lee Baker Buying and Selling Activity at Turning Point Therapeutics

This chart shows Brian Lee Baker's buying and selling at Turning Point Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Turning Point Therapeutics Company Overview

Turning Point Therapeutics logo
Turning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+ and NTRK+ advanced solid tumors. It also develops TPX-0022, a MET/SRC/CSF1R inhibitor, which is in Phase 1 SHIELD-1 clinical trial for patients with advanced solid tumors harboring genetic alterations in MET; TPX-0046, a RET inhibitor that is in 1/2 SWORD-1 clinical trial for patients with advanced solid tumors harboring RET genetic alterations; and TPX-0131, an ALK inhibitor, which is in Phase 1/2 FORGE-1 study for patient with advanced or metastatic TKI-pretreated ALK-positive NSCLC. Turning Point Therapeutics, Inc. was founded in 2013 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $76.01
Low: $76.01
High: $76.01

50 Day Range

MA: $75.83
Low: $74.80
High: $76.01

2 Week Range

Now: $76.01
Low: $23.77
High: $82.20

Volume

4,322 shs

Average Volume

1,137,726 shs

Market Capitalization

$3.81 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
JD Vance Predicts: Wall Street vs. Trump & Your Money
From Priority Gold   |   Ad
Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.
Get your free guide NOW before it's too late.